233 related articles for article (PubMed ID: 12228203)
1. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.
Bukowski R; Ernstoff MS; Gore ME; Nemunaitis JJ; Amato R; Gupta SK; Tendler CL
J Clin Oncol; 2002 Sep; 20(18):3841-9. PubMed ID: 12228203
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
3. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor.
Bex A; Mallo H; Kerst M; Haanen J; Horenblas S; de Gast GC
Cancer Immunol Immunother; 2005 Jul; 54(7):713-9. PubMed ID: 15627213
[TBL] [Abstract][Full Text] [Related]
4. Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b.
Lyrdal D; Stierner U; Lundstam S
Acta Oncol; 2009; 48(6):901-8. PubMed ID: 19274498
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
[TBL] [Abstract][Full Text] [Related]
10. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.
Dummer R; Garbe C; Thompson JA; Eggermont AM; Yoo K; Maier T; Bergstrom B
J Clin Oncol; 2006 Mar; 24(7):1188-94. PubMed ID: 16505439
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
Clark JI; Mehrabi J; Sosman JA; Logan TF; Margolin KA; Dutcher JP; Urba WJ; Ernstoff MS; McDermott DF; Lau AM; Atkins MB
J Immunother; 2007; 30(8):839-46. PubMed ID: 18049336
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma.
Feldman DR; Kondagunta GV; Schwartz L; Patil S; Ishill N; DeLuca J; Russo P; Motzer RJ
Clin Genitourin Cancer; 2008 Mar; 6(1):25-30. PubMed ID: 18501079
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
Atkins MB; Hodi FS; Thompson JA; McDermott DF; Hwu WJ; Lawrence DP; Dawson NA; Wong DJ; Bhatia S; James M; Jain L; Robey S; Shu X; Homet Moreno B; Perini RF; Choueiri TK; Ribas A
Clin Cancer Res; 2018 Apr; 24(8):1805-1815. PubMed ID: 29358500
[No Abstract] [Full Text] [Related]
16. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Eggermont AM; Suciu S; Santinami M; Testori A; Kruit WH; Marsden J; Punt CJ; Salès F; Gore M; MacKie R; Kusic Z; Dummer R; Hauschild A; Musat E; Spatz A; Keilholz U;
Lancet; 2008 Jul; 372(9633):117-126. PubMed ID: 18620949
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
19. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
Burris HA; Infante JR; Ansell SM; Nemunaitis JJ; Weiss GR; Villalobos VM; Sikic BI; Taylor MH; Northfelt DW; Carson WE; Hawthorne TR; Davis TA; Yellin MJ; Keler T; Bullock T
J Clin Oncol; 2017 Jun; 35(18):2028-2036. PubMed ID: 28463630
[TBL] [Abstract][Full Text] [Related]
20. Potential of interferon-alpha in solid tumours: part 1.
Decatris M; Santhanam S; O'Byrne K
BioDrugs; 2002; 16(4):261-81. PubMed ID: 12196039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
